It seems like a sensible lifecycle management maneuver for MRK insofar as Zetia/Vytorin go off-patent in the US in Apr 2017. However, MRK also has anacetrapib to consider when making such decisions.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.